Clin2
NCT05356351Possibly a fitNot yet recruiting

New drug combo before bladder cancer surgery

Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance

Treatments studied

Part of Cancer, Kidney & urinary clinical trials.

This trial tests a new combination of two drugs before bladder removal surgery for patients with HER2-positive muscle-invasive bladder cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
30 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are 18 to 75 years old.
  • You have bladder cancer that has grown into the muscle layer (stage T2-T4a) and has not spread to lymph nodes or other organs.
  • Your tumor is HER2 positive (tested as IHC 2+ or 3+).
  • You are planning to have surgery to remove your bladder (radical cystectomy).
  • You either cannot receive standard chemotherapy before surgery, or you choose not to.
  • You have not had chemotherapy, radiation, or other cancer treatment in the past 6 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07624201Not yet recruiting· Phase 2
Drug combination before bladder cancer surgery

This trial tests two drugs, trastuzumab rezetecan and adebrelimab, given before surgery for a type of bladder cancer that has grown into the muscle. The goal is to see if this combination can shrink the tumor and improve outcomes for patients whose cancer cells have a certain protein called HER2.

NCT07279597Not yet recruiting· Phase 2
Drug and radiation combination to save the bladder in HER2-positive bladder cancer

This study tests a combination of two drugs (toripalimab and RC48-ADC) plus radiation therapy to treat bladder cancer while keeping the bladder intact. It aims to see if this approach can control the cancer without needing to remove the bladder.

NCT07693959Recruiting· Phase 3
RC48 plus gemcitabine before bladder cancer surgery

This trial tests a combination of an antibody-drug conjugate (RC48) plus chemotherapy (gemcitabine) given before bladder removal surgery. It is for people with HER2-positive bladder cancer that has grown into the muscle layer.

Hefei, Anhui
NCT07296705Recruiting· Phase 2
New drug combo to save the bladder in HER2-positive bladder cancer

This trial tests combining two newer drugs (zanidatamab and tislelizumab) with standard chemotherapy before bladder surgery. The goal is to shrink the tumor so the bladder can be saved instead of removed.

Fuzhou, Fujian
NCT07639983Not yet recruiting· Phase 2
Trastuzumab rezetecan plus camrelizumab before surgery for HER2-positive bladder cancer

This trial tests whether giving a combination of two drugs before and after surgery can help people with HER2-positive bladder cancer that has grown into the bladder muscle. The goal is to see if this approach can shrink or control the cancer before the bladder is removed.

NCT07332351Not yet recruiting· Phase 2
Neoadjuvant combination therapy for muscle-invasive bladder cancer

This trial tests a combination of three drugs before bladder removal surgery in people with muscle-invasive bladder cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.

Seattle, Washington

Hear when a new Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.